{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:56:15Z","timestamp":1754160975777,"version":"3.41.2"},"reference-count":5,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>In this case report, a 72-year-old male haemodialysis patient with severe chronic kidney disease-associated pruritus (CKD-aP) was given difelikefalin (DFK) 50 \u03bcg \u00d7 3\/week after unsuccessful standard therapy including fatty cream, steroids, antihistamines, gabapentinoids, and UV-light. CKD-aP was verified by a dermatologist before DFK was given. After three weeks, CKD-aP had improved markedly. The worst itch numeric rate scale (range: 0-10) dropped to 0 from 7-8 prior to DFK. DFK caused drowsiness which disappeared when the treatment was paused. DFK dose was then reduced to 25 \u03bcg \u00d7 3\/week which was well tolerated. The skin healed, except for scars caused by scratching.<\/jats:p>","DOI":"10.61409\/v09240621","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:17:19Z","timestamp":1738646239000},"page":"1-4","source":"Crossref","is-referenced-by-count":0,"title":["Difelikefalin for severe chronic kidney disease-associated pruritus in a patient in dialysis"],"prefix":"10.61409","author":[{"given":"Gustav \u00d8sterlund","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista Dybtved","family":"Kj\u00e6rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Daugaard","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Lanot A, Bataille S, Rostoker G et al. Moderate-to-severe pruritus in untreated or non-responsive hemodialysis patients: results of the French prospective multicenter observational study Pruripreva. Clin Kidney J. 2023;16(7):1102-1112. https:\/\/doi.org\/10.1093\/ckj\/sfad032","DOI":"10.1093\/ckj\/sfad032"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Peters CD, Larsen G\u00d8, Kj\u00e6rgaard KD et al. #1151 The prevalence and disease burden of CKD associated pruritus in Danish dialysis patients and current treatment practices-preliminary results. Nephrology Dialysis Transplantation. 2024;39(1);gfae069-0777-1151. https:\/\/doi.org\/10.1093\/ndt\/gfae069.077","DOI":"10.1093\/ndt\/gfae069.077"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5(9):1387-1402. https:\/\/doi.org\/10.1016\/j.ekir.2020.04.027","DOI":"10.1016\/j.ekir.2020.04.027"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Fishbane S, Jamal A, Munera C et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382(3):222-232. https:\/\/doi.org\/10.1056\/NEJMoa1912770","DOI":"10.1056\/NEJMoa1912770"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Fishbane S, Wen W, Munera C et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Med. 2022;4(8):100513. https:\/\/doi.org\/10.1016\/j.xkme.2022.100513","DOI":"10.1016\/j.xkme.2022.100513"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T09:17:17Z","timestamp":1753694237000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V09240621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":5,"URL":"https:\/\/doi.org\/10.61409\/v09240621","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}